HOUSTON, Feb. 20, 2024 /PRNewswire/ — FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”) is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and…
Month: February 2024
HOUSTON, Feb. 20, 2024 /PRNewswire/ — FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”) is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and…
Gildan, a leading apparel manufacturer, is pleased to announce that the Company will donate USD $250,000 to World Vision Honduras to support the continued implementation of the Childhood Education and Transformation (ETN) program in Honduras.
The longstanding 11-year partnership between Gildan and World Vision Honduras, underscores a shared commitment to sustainable development, enhancing the socioemotional and socioenvironmental skills of children, and fostering a deeper sense of environmental responsibility in the communities of Villanueva, Choloma, and now Quimistán. Through these combined efforts, the ETN program has become synonymous with educational excellence and environmental advocacy, leaving an indelible mark on the regions it serves.
“We are proud of our partnership with World Vision. The recent completion of Phase III of the program benefited over 204,000 children by teaching them valuable skills across various subject areas. We also strengthened 68 educational networks fostering green and safe school environments, and empowered over 3,000 educators with skills in ICT, environmental stewardship, and socioemotional growth,” says Claudia Sandoval, Vice-President of Global Social Compliance and Environmental Affairs at Gildan.
The Company’s additional investment will directly support the activation of Phase IV, which includes training over 300 educators in socioemotional well-being and climate change mitigation. Phase IV is expected to positively impact 10,000 children in the region and have an indirect reach of over 300,000 children across 400 schools, highlighting its far-reaching impact on Honduran youth.
Phase IV of the program will also have an enhanced focus on environmental protection and holistic child development. A key objective will include the gradual certification of schools as “Green and Safe Schools,” a regulation from the Ministry of Education aimed at strengthening environmental education in schools nationwide, which Gildan and World Vision Honduras will work to facilitate through oversight of the certification process of schools within the program.
The additional donation reaffirms the enduring impact of the partnership between Gildan and World Vision Honduras, underscoring the importance of collaborative efforts in driving sustainable change. With over $700,000 donated to World Vision Honduras alone, and more than 351,000 children positively impacted to date, this partnership serves as a testament to the power of collective action in addressing the most pressing challenges facing vulnerable communities.
Under its Next Generation ESG strategy, Gildan remains steadfast in its commitment to nurturing the potential of Honduran children and safeguarding the environment for future generations. Through its continued collaboration with World Vision Honduras and its unwavering dedication, Gildan strives to create a brighter and more sustainable future for all.
To learn more about Gildan’s respect for communities, click here.
Gildan, a leading apparel manufacturer, is pleased to announce that the Company will donate USD $250,000 to World Vision Honduras to support the continued implementation of the Childhood Education and Transformation (ETN) program in Honduras.
The longstanding 11-year partnership between Gildan and World Vision Honduras, underscores a shared commitment to sustainable development, enhancing the socioemotional and socioenvironmental skills of children, and fostering a deeper sense of environmental responsibility in the communities of Villanueva, Choloma, and now Quimistán. Through these combined efforts, the ETN program has become synonymous with educational excellence and environmental advocacy, leaving an indelible mark on the regions it serves.
“We are proud of our partnership with World Vision. The recent completion of Phase III of the program benefited over 204,000 children by teaching them valuable skills across various subject areas. We also strengthened 68 educational networks fostering green and safe school environments, and empowered over 3,000 educators with skills in ICT, environmental stewardship, and socioemotional growth,” says Claudia Sandoval, Vice-President of Global Social Compliance and Environmental Affairs at Gildan.
The Company’s additional investment will directly support the activation of Phase IV, which includes training over 300 educators in socioemotional well-being and climate change mitigation. Phase IV is expected to positively impact 10,000 children in the region and have an indirect reach of over 300,000 children across 400 schools, highlighting its far-reaching impact on Honduran youth.
Phase IV of the program will also have an enhanced focus on environmental protection and holistic child development. A key objective will include the gradual certification of schools as “Green and Safe Schools,” a regulation from the Ministry of Education aimed at strengthening environmental education in schools nationwide, which Gildan and World Vision Honduras will work to facilitate through oversight of the certification process of schools within the program.
The additional donation reaffirms the enduring impact of the partnership between Gildan and World Vision Honduras, underscoring the importance of collaborative efforts in driving sustainable change. With over $700,000 donated to World Vision Honduras alone, and more than 351,000 children positively impacted to date, this partnership serves as a testament to the power of collective action in addressing the most pressing challenges facing vulnerable communities.
Under its Next Generation ESG strategy, Gildan remains steadfast in its commitment to nurturing the potential of Honduran children and safeguarding the environment for future generations. Through its continued collaboration with World Vision Honduras and its unwavering dedication, Gildan strives to create a brighter and more sustainable future for all.
To learn more about Gildan’s respect for communities, click here.
Originally published on HARMAN Insights
Medical errors pose substantial challenges including patient harm, healthcare system strain and potentially tragic loss of life. This white paper addresses the critical issue of medical errors within the healthcare industry and presents comprehensive strategies to mitigate these errors to help ensure safer and more effective patient care.
In this paper, we discuss:
The root causes of medical errors and examine them across medical practices, medical device manufacturers and pharmaceutical companiesHow proactive measures, such as education, awareness and technology integration, can significantly reduce such errorsThe transformative potential of digitalization in healthcare and provide insights into how it can mitigate risks and improve overall effectivenessThe improvements required in healthcare, medical device manufacturing and pharmaceuticals to create a safer healthcare ecosystem
By addressing all these areas, healthcare organizations, professionals and stakeholders can collaborate to enhance patient safety, restore trust and ultimately, save lives.
Current challenges: The toll of medical errors and patient harm
Medical errors remain a pervasive and critical concern within the healthcare industry. These errors lead to many adverse outcomes. Recent statistics reveal the gravity of the situation.
Fatalities
Medical errors are estimated to be one of the leading causes of death worldwide, with studies suggesting they claim hundreds of thousands of lives annually.
Financial impact
Medical errors result in substantial financial burdens on healthcare systems, contributing to increased healthcare costs and malpractice claims.
Patient confidence
Medical errors erode patient trust in healthcare systems, leading to reduced patient satisfaction and engagement in their care.
The role of healthcare in the cause and effect of medical errors
When healthcare, medical device and pharmaceutical companies create situations where errors are made, it can significantly impact patient outcomes. But a growing awareness of potential errors can help in addressing and preventing them.
Healthcare providers: Misdiagnosis, medication errors, surgical complications and communication breakdowns often originate from healthcare provider environments where clinical and operational staff may be overworked, fatigued or inadequately trained.Medical device manufacturing: Complex medical devices are integral to patient care but can contribute to errors when improperly calibrated, maintained or operated. Software glitches and user interface issues can also pose risks.Pharmaceutical companies: Medication errors, including prescription and dispensing mistakes, can occur due to unclear labeling, packaging or improper drug information dissemination.
Root causes of medical errors and examples
The occurrence of medical errors is often rooted in multiple factors, including complex healthcare systems, communication challenges and the pervasive issue of provider burnout. To proactively mitigate errors, medical companies require a comprehensive understanding of these underlying root causes.
Complex healthcare systems: The inherent complexity of modern healthcare, involving numerous steps, providers and technologies, contributes to errors. For example, a mix-up in patient records can lead to misdiagnosis or incorrect treatment.Communication challenges: Poor communication among healthcare teams as well as with patients can lead to misunderstandings and critical errors. A lack of clear handoff procedures during shift changes can result in critical missed information.Provider burnout: Overworked and stressed healthcare providers are more prone to errors, impacting patient care quality. An exhausted nurse administering the wrong medication dose exemplifies this issue.
Strategies to prevent medical errors
Continuous education and awareness campaigns are essential for both healthcare providers and patients to recognize and prevent errors. To that end, effective strategies include:
Standardized protocols: Implement standardized protocols and guidelines to reduce variability in care and minimize errors. For instance, standardized surgical checklists prevent crucial steps from being missed.Patient involvement: Empower patients to actively participate in their healthcare decisions, such as reviewing medication lists for accuracy and reporting any discrepancies to their healthcare providers.Technology integration: Embrace technology to improve patient safety, including electronic health records (EHRs) for streamlined information sharing and decision support systems to assist healthcare providers in making informed decisions.Patient education and engagement: Develop patient education platforms that provide clear, easy-to-understand information about medications, treatment plans and potential side effects. Use AI-driven chatbots or virtual assistants to engage with patients and answer their healthcare-related questions promptly.Data integration and interoperability: Ensure seamless data exchange and interoperability between healthcare systems, EHRs, IoT
devices and patient apps to provide a comprehensive view of a patient’s health. Use AI-powered data analytics to identify trends and potential issues related to medication adherence or treatment effectiveness.Provider training and decision support: Offer training programs for healthcare providers to effectively use AI and digital tools in patient care. Implement AI-driven clinical decision support systems that provide evidence-based recommendations for medication management and treatment plans.Continuous improvement and feedback loops: Establish feedback loops with patients and healthcare providers to gather insights on the effectiveness of digital interventions and identify areas for improvement. Continuously update and refine digital tools and interventions based on real-world data and user feedback.
By integrating these strategies into healthcare systems, organizations can significantly reduce the risk of medical errors, improve patient outcomes and enhance the overall quality and safety of healthcare delivery.
How digitalization can help mitigate risks of medical errors and improve effectiveness
Healthcare
Solution: Electronic Health Records (EHRs)
Solution Impact: This reduces the risk of miscommunication and errors due to incomplete or inaccurate
patient data.
Solution Recommendation: EHRs centralize patient information, making it accessible to authorized healthcare providers.
Solution: Remote Care
Solution Impact: Remote consultations and monitoring through remote care platforms. This not only increases accessibility to healthcare but also reduces the risk of errors associated with in-person visits, such as misdiagnoses or treatment delays.
Solution Recommendation: Enable continuous remote monitoring of patients, especially those with chronic conditions, to detect issues early and adjust treatment plans accordingly.
Solution: IoT for Real-time Monitoring
Solution Impact: Implement IoT-enabled wearable devices and sensors for continuous patient monitoring. These devices can track vital signs, glucose levels, medication adherence and more in real-time.
Solution Recommendation: Use IoT data to create early warning systems that alert healthcare providers to abnormal readings or patient non-compliance,
allowing for timely intervention.
Solution: Clinical Decision Support Systems
Solution Impact: Utilize data analytics and AI to assist healthcare providers in making accurate and evidence-based decisions.
Solution Recommendation: They can recommend appropriate treatments and identify potential issues, reducing diagnostic and treatment errors.
Solution: Patient Portals
Solution Impact: Empower individuals to actively participate in their healthcare through digital patient portals.
Solution Recommendation: Patients can review their medical records, medications and lab results for accuracy, and report any discrepancies to their healthcare providers.
Solution: Medication Adherence Solutions
Solution Impact: Develop medication adherence apps and platforms that provide patients with reminders, educational content and personalized medication schedules.
Solution Recommendation: Incorporate IoT-connected pill dispensers that track medication usage and send adherence data to both patients and healthcare providers.
Solution: AI/ML for Diagnosis and Treatment
Solution Impact: Utilize AI algorithms to analyze medical images, lab results and patient histories for more accurate and timely diagnoses.
Solution Recommendation: Implement ML models that can predict patient-specific risks and recommend personalized treatment plans, reducing the likelihood of prescription errors.
Solution: Digital Therapeutics
Solution Impact: Incorporate digital therapeutics into treatment plans for chronic conditions. These therapeutic interventions can include mobile apps, wearables and software programs that provide evidence-based treatments and interventions.
Solution Recommendation: Monitor patient progress through digital therapeutics and adjust treatment plans in real-time based on patient responses and outcomes.
Solution: Predictive Analytics
Solution Impact: Utilize AI-driven predictive analytics to identify patients at higher risk of medical errors, such as those with complex medication regimens or comorbidities.
Solution Recommendation: Implement personalized care plans and interventions for high-risk patients to reduce the chances of medication errors or treatment complications.
Medical Devices
Solution: Connected Medical Devices
Solution Impact: Transmit real-time data, through IoT-enabled medical devices, to healthcare providers, facilitating remote monitoring and early detection of issues.
Solution Recommendation: This connectivity enhances patient safety and reduces the risk of device-related errors.
Solution: Barcode Medication Administration (BCMA)
Solution Impact: Use barcodes to verify medications, helping ensure that patients receive the correct drugs and dosages.
Solution Recommendation: These systems significantly reduce medication errors in healthcare settings.
Solution: Quality Control and Maintenance
Solution Impact: Automate, through digital tools, quality control checks and maintenance schedules for medical devices.
Solution Recommendation: This reduces the risk of device malfunctions due to human error and ensures proper use and maintenance of medical devices to reduce errors. It’s essential that users understand the devices they are using thoroughly.
Pharmaceuticals
Solution: Drug Safety Monitoring
Solution Impact: Track adverse drug reactions and safety data in real-time through digitalization.
Solution Recommendation: This proactive approach allows pharmaceutical companies to identify potential risks and take corrective actions promptly.
Solution: Supply Chain Transparency
Solution Impact: Enhance transparency, through blockchain, in pharmaceutical supply chains, reducing the risk of counterfeit medications entering the market.
Solution Recommendation: This allows patients to have greater confidence in the authenticity and safety of their medications.
Solution: Clinical Trials
Solution Impact: Streamline the management of clinical trials through digital, helping ensure data integrity and adherence to protocols.
Solution Recommendation: This reduces errors in the research and development phases of pharmaceutical products.
Solution: Interoperability
Solution Impact: Protect patient data with stringent and robust cybersecurity measures, especially as more healthcare processes become digital.
Solution Recommendation: Standardized data formats and interfaces are essential.
Solution: Data Security
Solution Impact: Strive for greater interoperability to help ensure seamless data sharing and communication.
Solution Recommendation: Regular security audits and training are necessary to safeguard against data breaches.
Solution: Regulatory Adaptation
Solution Impact: Adhere to clear regulatory guidelines and standards for digital healthcare, medical devices and pharmaceuticals.
Solution Recommendation: This helps ensure patient safety and product efficacy.
Solution: Education and Training
Solution Impact: Build comprehensive training on digital tools and systems.
Solution Recommendation: When used effectively, these tools can prevent critical medical errors.
Solution: Patient Education
Solution Impact: Educate patients and caregivers on how to use digital tools and portals effectively and securely.
Solution Recommendation: A patient’s active participation is vital in reducing medical errors.
In conclusion
Mitigating medical errors necessitates a collective and proactive approach. The outlined strategies, encompassing education, standardized protocols, patient involvement and digitalization, offer a comprehensive roadmap for systemic improvement. The integration of technologies such as EHRs, remote care platforms and AI, including private large language models (LLMs) and generative AI, presents transformative opportunities to create a culture of continuous improvement and technological innovation.
Download: “Prescription for Safer Healthcare: Strategies to Mitigate Medical Errors” Whitepaper here.
Author
ALOK ANAND
Associate Director, Healthcare & Life Sciences
HARMAN Digital Transformation Solutions
Author
DR. PRIYANKA BARUA
Head of Quality
Leading Multi-speciality Hospital in India
Originally published on HARMAN Insights
Medical errors pose substantial challenges including patient harm, healthcare system strain and potentially tragic loss of life. This white paper addresses the critical issue of medical errors within the healthcare industry and presents comprehensive strategies to mitigate these errors to help ensure safer and more effective patient care.
In this paper, we discuss:
The root causes of medical errors and examine them across medical practices, medical device manufacturers and pharmaceutical companiesHow proactive measures, such as education, awareness and technology integration, can significantly reduce such errorsThe transformative potential of digitalization in healthcare and provide insights into how it can mitigate risks and improve overall effectivenessThe improvements required in healthcare, medical device manufacturing and pharmaceuticals to create a safer healthcare ecosystem
By addressing all these areas, healthcare organizations, professionals and stakeholders can collaborate to enhance patient safety, restore trust and ultimately, save lives.
Current challenges: The toll of medical errors and patient harm
Medical errors remain a pervasive and critical concern within the healthcare industry. These errors lead to many adverse outcomes. Recent statistics reveal the gravity of the situation.
Fatalities
Medical errors are estimated to be one of the leading causes of death worldwide, with studies suggesting they claim hundreds of thousands of lives annually.
Financial impact
Medical errors result in substantial financial burdens on healthcare systems, contributing to increased healthcare costs and malpractice claims.
Patient confidence
Medical errors erode patient trust in healthcare systems, leading to reduced patient satisfaction and engagement in their care.
The role of healthcare in the cause and effect of medical errors
When healthcare, medical device and pharmaceutical companies create situations where errors are made, it can significantly impact patient outcomes. But a growing awareness of potential errors can help in addressing and preventing them.
Healthcare providers: Misdiagnosis, medication errors, surgical complications and communication breakdowns often originate from healthcare provider environments where clinical and operational staff may be overworked, fatigued or inadequately trained.Medical device manufacturing: Complex medical devices are integral to patient care but can contribute to errors when improperly calibrated, maintained or operated. Software glitches and user interface issues can also pose risks.Pharmaceutical companies: Medication errors, including prescription and dispensing mistakes, can occur due to unclear labeling, packaging or improper drug information dissemination.
Root causes of medical errors and examples
The occurrence of medical errors is often rooted in multiple factors, including complex healthcare systems, communication challenges and the pervasive issue of provider burnout. To proactively mitigate errors, medical companies require a comprehensive understanding of these underlying root causes.
Complex healthcare systems: The inherent complexity of modern healthcare, involving numerous steps, providers and technologies, contributes to errors. For example, a mix-up in patient records can lead to misdiagnosis or incorrect treatment.Communication challenges: Poor communication among healthcare teams as well as with patients can lead to misunderstandings and critical errors. A lack of clear handoff procedures during shift changes can result in critical missed information.Provider burnout: Overworked and stressed healthcare providers are more prone to errors, impacting patient care quality. An exhausted nurse administering the wrong medication dose exemplifies this issue.
Strategies to prevent medical errors
Continuous education and awareness campaigns are essential for both healthcare providers and patients to recognize and prevent errors. To that end, effective strategies include:
Standardized protocols: Implement standardized protocols and guidelines to reduce variability in care and minimize errors. For instance, standardized surgical checklists prevent crucial steps from being missed.Patient involvement: Empower patients to actively participate in their healthcare decisions, such as reviewing medication lists for accuracy and reporting any discrepancies to their healthcare providers.Technology integration: Embrace technology to improve patient safety, including electronic health records (EHRs) for streamlined information sharing and decision support systems to assist healthcare providers in making informed decisions.Patient education and engagement: Develop patient education platforms that provide clear, easy-to-understand information about medications, treatment plans and potential side effects. Use AI-driven chatbots or virtual assistants to engage with patients and answer their healthcare-related questions promptly.Data integration and interoperability: Ensure seamless data exchange and interoperability between healthcare systems, EHRs, IoT
devices and patient apps to provide a comprehensive view of a patient’s health. Use AI-powered data analytics to identify trends and potential issues related to medication adherence or treatment effectiveness.Provider training and decision support: Offer training programs for healthcare providers to effectively use AI and digital tools in patient care. Implement AI-driven clinical decision support systems that provide evidence-based recommendations for medication management and treatment plans.Continuous improvement and feedback loops: Establish feedback loops with patients and healthcare providers to gather insights on the effectiveness of digital interventions and identify areas for improvement. Continuously update and refine digital tools and interventions based on real-world data and user feedback.
By integrating these strategies into healthcare systems, organizations can significantly reduce the risk of medical errors, improve patient outcomes and enhance the overall quality and safety of healthcare delivery.
How digitalization can help mitigate risks of medical errors and improve effectiveness
Healthcare
Solution: Electronic Health Records (EHRs)
Solution Impact: This reduces the risk of miscommunication and errors due to incomplete or inaccurate
patient data.
Solution Recommendation: EHRs centralize patient information, making it accessible to authorized healthcare providers.
Solution: Remote Care
Solution Impact: Remote consultations and monitoring through remote care platforms. This not only increases accessibility to healthcare but also reduces the risk of errors associated with in-person visits, such as misdiagnoses or treatment delays.
Solution Recommendation: Enable continuous remote monitoring of patients, especially those with chronic conditions, to detect issues early and adjust treatment plans accordingly.
Solution: IoT for Real-time Monitoring
Solution Impact: Implement IoT-enabled wearable devices and sensors for continuous patient monitoring. These devices can track vital signs, glucose levels, medication adherence and more in real-time.
Solution Recommendation: Use IoT data to create early warning systems that alert healthcare providers to abnormal readings or patient non-compliance,
allowing for timely intervention.
Solution: Clinical Decision Support Systems
Solution Impact: Utilize data analytics and AI to assist healthcare providers in making accurate and evidence-based decisions.
Solution Recommendation: They can recommend appropriate treatments and identify potential issues, reducing diagnostic and treatment errors.
Solution: Patient Portals
Solution Impact: Empower individuals to actively participate in their healthcare through digital patient portals.
Solution Recommendation: Patients can review their medical records, medications and lab results for accuracy, and report any discrepancies to their healthcare providers.
Solution: Medication Adherence Solutions
Solution Impact: Develop medication adherence apps and platforms that provide patients with reminders, educational content and personalized medication schedules.
Solution Recommendation: Incorporate IoT-connected pill dispensers that track medication usage and send adherence data to both patients and healthcare providers.
Solution: AI/ML for Diagnosis and Treatment
Solution Impact: Utilize AI algorithms to analyze medical images, lab results and patient histories for more accurate and timely diagnoses.
Solution Recommendation: Implement ML models that can predict patient-specific risks and recommend personalized treatment plans, reducing the likelihood of prescription errors.
Solution: Digital Therapeutics
Solution Impact: Incorporate digital therapeutics into treatment plans for chronic conditions. These therapeutic interventions can include mobile apps, wearables and software programs that provide evidence-based treatments and interventions.
Solution Recommendation: Monitor patient progress through digital therapeutics and adjust treatment plans in real-time based on patient responses and outcomes.
Solution: Predictive Analytics
Solution Impact: Utilize AI-driven predictive analytics to identify patients at higher risk of medical errors, such as those with complex medication regimens or comorbidities.
Solution Recommendation: Implement personalized care plans and interventions for high-risk patients to reduce the chances of medication errors or treatment complications.
Medical Devices
Solution: Connected Medical Devices
Solution Impact: Transmit real-time data, through IoT-enabled medical devices, to healthcare providers, facilitating remote monitoring and early detection of issues.
Solution Recommendation: This connectivity enhances patient safety and reduces the risk of device-related errors.
Solution: Barcode Medication Administration (BCMA)
Solution Impact: Use barcodes to verify medications, helping ensure that patients receive the correct drugs and dosages.
Solution Recommendation: These systems significantly reduce medication errors in healthcare settings.
Solution: Quality Control and Maintenance
Solution Impact: Automate, through digital tools, quality control checks and maintenance schedules for medical devices.
Solution Recommendation: This reduces the risk of device malfunctions due to human error and ensures proper use and maintenance of medical devices to reduce errors. It’s essential that users understand the devices they are using thoroughly.
Pharmaceuticals
Solution: Drug Safety Monitoring
Solution Impact: Track adverse drug reactions and safety data in real-time through digitalization.
Solution Recommendation: This proactive approach allows pharmaceutical companies to identify potential risks and take corrective actions promptly.
Solution: Supply Chain Transparency
Solution Impact: Enhance transparency, through blockchain, in pharmaceutical supply chains, reducing the risk of counterfeit medications entering the market.
Solution Recommendation: This allows patients to have greater confidence in the authenticity and safety of their medications.
Solution: Clinical Trials
Solution Impact: Streamline the management of clinical trials through digital, helping ensure data integrity and adherence to protocols.
Solution Recommendation: This reduces errors in the research and development phases of pharmaceutical products.
Solution: Interoperability
Solution Impact: Protect patient data with stringent and robust cybersecurity measures, especially as more healthcare processes become digital.
Solution Recommendation: Standardized data formats and interfaces are essential.
Solution: Data Security
Solution Impact: Strive for greater interoperability to help ensure seamless data sharing and communication.
Solution Recommendation: Regular security audits and training are necessary to safeguard against data breaches.
Solution: Regulatory Adaptation
Solution Impact: Adhere to clear regulatory guidelines and standards for digital healthcare, medical devices and pharmaceuticals.
Solution Recommendation: This helps ensure patient safety and product efficacy.
Solution: Education and Training
Solution Impact: Build comprehensive training on digital tools and systems.
Solution Recommendation: When used effectively, these tools can prevent critical medical errors.
Solution: Patient Education
Solution Impact: Educate patients and caregivers on how to use digital tools and portals effectively and securely.
Solution Recommendation: A patient’s active participation is vital in reducing medical errors.
In conclusion
Mitigating medical errors necessitates a collective and proactive approach. The outlined strategies, encompassing education, standardized protocols, patient involvement and digitalization, offer a comprehensive roadmap for systemic improvement. The integration of technologies such as EHRs, remote care platforms and AI, including private large language models (LLMs) and generative AI, presents transformative opportunities to create a culture of continuous improvement and technological innovation.
Download: “Prescription for Safer Healthcare: Strategies to Mitigate Medical Errors” Whitepaper here.
Author
ALOK ANAND
Associate Director, Healthcare & Life Sciences
HARMAN Digital Transformation Solutions
Author
DR. PRIYANKA BARUA
Head of Quality
Leading Multi-speciality Hospital in India
Leucipa has seen production increases upwards of 3% and 75% efficiency gains in engineering time for customers
Cordant’s intelligent connected hardware, software and value-added services are delivering an increase in yield and productivity, lowering costs and improving the safety of customer operations
These digital solutions deliver more intelligent operations for customers across the energy value chain
FLORENCE, Italy, February 20, 2024 /3BL/ – One year after introducing multiple new digital solutions and investments Baker Hughes, an energy technology company, during its 24th Annual Meeting in Florence, Italy shared an update on how its digital portfolio is improving efficiency and performance across the energy industry.
“Last year, Baker Hughes shared a vision to deliver intelligent operations to reduce business uncertainty and costs, improve productivity, and meet decarbonization goals for our customers. Today, I am pleased we continue to see progress as we deliver digital outcomes for our customers in field production and processing as well as heavy process industries,” said Lorenzo Simonelli, chairman and CEO of Baker Hughes. “From the development of new predictive AI features for oil and gas customers to improved reliability and safety outcomes for industrial segments, we continue to invest and innovate in the digital space to improve our customers’ operations.”
Since first launching in 2023, the Leucipa™ automated field production solution has matured and expanded. Designed to help oil and gas operators proactively manage production and increase engineering efficiency, the Leucipa technology is now deployed across 20 countries and over 100 reservoirs.
Results on the delivered value to existing customers have been swift and significant, with production increases upwards of 3% and 75% efficiency gains in engineering time. For one customer in North America, Leucipa delivered even greater increases, with a production uplift of 14% and an annualized incremental margin of $6 million across 4,000 wells. Additional functionality releases for the Leucipa solution are anticipated for mid-2024.
Following the January 2023 launch, existing digital industrial offerings were converged to form the edge-to-enterprise Cordant™ Solutions for improving operational performance for energy and industrial customers. It comprises intelligent connected hardware, hybrid domain models based on AI/physics and first principles, software, and value-added services. Customers leveraging Cordant have seen an increase in yield and productivity, lower costs, and an improvement in the safety of their operations, including:
an industrial company has seen a throughput improvement of approximately 1-2%, in early deployment, helping to close the gap to potential and deliver thousands of tons in incremental yield; andan international oil company that saw a 21% reduction in man hours at an offshore site, and a 10% improvement in production deferrals helping to drive efficiency and improve safety of operations.
Together, these digital solutions deliver customer outcomes across the energy value chain, from improving efficiency in drilling and production in the upstream, to improving the management of assets and processes for industrial customers, and beyond. Baker Hughes remains committed to delivering the best solutions for its customers and staying at the forefront of digital innovation.
About Baker Hughes: Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner, and more efficient for people and the planet. Visit us at bakerhughes.com.
For more information, please contact:
Media Relations
Chiara Toniato +39 3463823419 chiara.toniato@bakerhughes.com
Adrienne M. Lynch +1 713-906-8407 adrienne.lynch@bakerhughes.com
Leucipa has seen production increases upwards of 3% and 75% efficiency gains in engineering time for customers
Cordant’s intelligent connected hardware, software and value-added services are delivering an increase in yield and productivity, lowering costs and improving the safety of customer operations
These digital solutions deliver more intelligent operations for customers across the energy value chain
FLORENCE, Italy, February 20, 2024 /3BL/ – One year after introducing multiple new digital solutions and investments Baker Hughes, an energy technology company, during its 24th Annual Meeting in Florence, Italy shared an update on how its digital portfolio is improving efficiency and performance across the energy industry.
“Last year, Baker Hughes shared a vision to deliver intelligent operations to reduce business uncertainty and costs, improve productivity, and meet decarbonization goals for our customers. Today, I am pleased we continue to see progress as we deliver digital outcomes for our customers in field production and processing as well as heavy process industries,” said Lorenzo Simonelli, chairman and CEO of Baker Hughes. “From the development of new predictive AI features for oil and gas customers to improved reliability and safety outcomes for industrial segments, we continue to invest and innovate in the digital space to improve our customers’ operations.”
Since first launching in 2023, the Leucipa™ automated field production solution has matured and expanded. Designed to help oil and gas operators proactively manage production and increase engineering efficiency, the Leucipa technology is now deployed across 20 countries and over 100 reservoirs.
Results on the delivered value to existing customers have been swift and significant, with production increases upwards of 3% and 75% efficiency gains in engineering time. For one customer in North America, Leucipa delivered even greater increases, with a production uplift of 14% and an annualized incremental margin of $6 million across 4,000 wells. Additional functionality releases for the Leucipa solution are anticipated for mid-2024.
Following the January 2023 launch, existing digital industrial offerings were converged to form the edge-to-enterprise Cordant™ Solutions for improving operational performance for energy and industrial customers. It comprises intelligent connected hardware, hybrid domain models based on AI/physics and first principles, software, and value-added services. Customers leveraging Cordant have seen an increase in yield and productivity, lower costs, and an improvement in the safety of their operations, including:
an industrial company has seen a throughput improvement of approximately 1-2%, in early deployment, helping to close the gap to potential and deliver thousands of tons in incremental yield; andan international oil company that saw a 21% reduction in man hours at an offshore site, and a 10% improvement in production deferrals helping to drive efficiency and improve safety of operations.
Together, these digital solutions deliver customer outcomes across the energy value chain, from improving efficiency in drilling and production in the upstream, to improving the management of assets and processes for industrial customers, and beyond. Baker Hughes remains committed to delivering the best solutions for its customers and staying at the forefront of digital innovation.
About Baker Hughes: Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner, and more efficient for people and the planet. Visit us at bakerhughes.com.
For more information, please contact:
Media Relations
Chiara Toniato +39 3463823419 chiara.toniato@bakerhughes.com
Adrienne M. Lynch +1 713-906-8407 adrienne.lynch@bakerhughes.com
– Company Also Ranked in Top 5 of Pharmaceuticals and Biotech Industry –
FOSTER CITY, Calif., February 20, 2024 /3BL/ – Gilead Sciences, Inc. (Nasdaq: GILD) announced the company has been named one of America’s Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead’s longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and communities the company serves, employees and shareholders – while working to create a healthier world for all people. Gilead was recognized on the top 100 list and ranked fifth in the Pharmaceuticals and Biotech industry.
“We have set ambitious goals that are helping to further embed corporate responsibility into our business and honor our commitment to create a better world for future generations,” said Carmen Villar, Vice President, Public Affairs, Gilead Sciences. “We are proud to cultivate sustainable practices and an inclusive culture, while providing equitable opportunities for the communities we serve.”
Gilead’s Environmental, Social and Governance (ESG) strategy aims to position the company as the biotech employer and partner of choice while delivering shareholder value in a sustainable, responsible manner. Examples of Gilead’s commitment to ESG include:
Expanding health equity around the world through programs that promote health system sustainability, strengthen infrastructure and provide education and financial supportIncreasing access to medicines in low- and lower-middle income countries, including voluntary licensing for Gilead’s HIV, hepatitis C and COVID-19 treatmentsCreating an inclusive workplace that is representative of the diverse communities the company servesContinuing to evolve the company’s environmental sustainability program while progressing against ambitious goals focused on carbon, water, waste and packaging
Each year, JUST Capital collects and analyzes corporate data to evaluate the 1,000 largest public U.S. companies across 20 issues identified through comprehensive, ongoing public opinion research on Americans’ attitudes toward responsible corporate behavior. For more about the JUST Capital rankings, visit: https://justcapital.com/reports/just-capital-and-cnbc-release-the-2024-rankings-of-americas-most-just-companies/
This recognition follows Gilead’s recent announcement it was named to the Dow Jones Sustainability World Index for the third consecutive year, as well as the Dow Jones Sustainability North America Index, which highlight the most sustainable companies around the world based on a corporate sustainability assessment.
Details on Gilead’s ESG commitments, goals and progress can be found in the company’s Environmental Social Governance Impact Report, which is based on internationally recognized guidelines from the Global Reporting Initiative, the Sustainability Accounting Standards Board, the Taskforce on Climate Related Financial Disclosures and the United Nations Sustainable Development Goals. Learn more about Gilead’s commitment to ESG at https://www.gilead.com/purpose/esg.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
Jacquie Ross, Investors
investor_relations@gilead.com
Meaghan Smith, Media
public_affairs@gilead.com
– Company Also Ranked in Top 5 of Pharmaceuticals and Biotech Industry –
FOSTER CITY, Calif., February 20, 2024 /3BL/ – Gilead Sciences, Inc. (Nasdaq: GILD) announced the company has been named one of America’s Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead’s longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and communities the company serves, employees and shareholders – while working to create a healthier world for all people. Gilead was recognized on the top 100 list and ranked fifth in the Pharmaceuticals and Biotech industry.
“We have set ambitious goals that are helping to further embed corporate responsibility into our business and honor our commitment to create a better world for future generations,” said Carmen Villar, Vice President, Public Affairs, Gilead Sciences. “We are proud to cultivate sustainable practices and an inclusive culture, while providing equitable opportunities for the communities we serve.”
Gilead’s Environmental, Social and Governance (ESG) strategy aims to position the company as the biotech employer and partner of choice while delivering shareholder value in a sustainable, responsible manner. Examples of Gilead’s commitment to ESG include:
Expanding health equity around the world through programs that promote health system sustainability, strengthen infrastructure and provide education and financial supportIncreasing access to medicines in low- and lower-middle income countries, including voluntary licensing for Gilead’s HIV, hepatitis C and COVID-19 treatmentsCreating an inclusive workplace that is representative of the diverse communities the company servesContinuing to evolve the company’s environmental sustainability program while progressing against ambitious goals focused on carbon, water, waste and packaging
Each year, JUST Capital collects and analyzes corporate data to evaluate the 1,000 largest public U.S. companies across 20 issues identified through comprehensive, ongoing public opinion research on Americans’ attitudes toward responsible corporate behavior. For more about the JUST Capital rankings, visit: https://justcapital.com/reports/just-capital-and-cnbc-release-the-2024-rankings-of-americas-most-just-companies/
This recognition follows Gilead’s recent announcement it was named to the Dow Jones Sustainability World Index for the third consecutive year, as well as the Dow Jones Sustainability North America Index, which highlight the most sustainable companies around the world based on a corporate sustainability assessment.
Details on Gilead’s ESG commitments, goals and progress can be found in the company’s Environmental Social Governance Impact Report, which is based on internationally recognized guidelines from the Global Reporting Initiative, the Sustainability Accounting Standards Board, the Taskforce on Climate Related Financial Disclosures and the United Nations Sustainable Development Goals. Learn more about Gilead’s commitment to ESG at https://www.gilead.com/purpose/esg.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
Jacquie Ross, Investors
investor_relations@gilead.com
Meaghan Smith, Media
public_affairs@gilead.com